Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05981053
Other study ID # #26122021
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 15, 2022
Est. completion date June 30, 2023

Study information

Verified date August 2023
Source PINER Pastor Manfredi Winery
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this clinical trial is to compare the health conditions of the participating population before and after an intervention with Resveratrol enriched wine. The main questions it aims to answer are: 1. • The consumption of wine enriched with resveratrol could slow down or reverse the biological age ? 2. • The consumption of wine enriched with resveratrol could improve body composition fat mass / muscle mass ? The participants will be evaluated at the beginning and at the end of the clinical trial and will adopt only one change in their habits, that is, change the usual wine they consume with their meals for a wine enriched with resveratrol, in a moderate measure, 250 cc for men and 125 cc/day for women. The design of the study will be that each volunteer is their own control, pre and post intervention.


Description:

Study objectives The objective of the study is to determine the possible relationship between the consumption of pure Malbec wine 100% enriched with pure resveratrol (150 mg/L of wine) ingested during meals, with biomarkers (oxidative stress, DNA damage, antioxidant defenses and chronic systemic inflammation in blood and urine), generated in the body by the damage produced by the oxidative stress of metabolism, age and chronic pathologies. Procedures to follow 1. First visit A doctor will take details of your medical history, perform a complete physical examination, and explain the reasons for the study. If you meet the criteria and are eligible to be included in the study, you will only be told not to take dietary supplements or antioxidants and you will be seen again in the office two weeks later. At that time, you will be asked to carry out a blood laboratory analysis. These will be the Baseline Controls. 2. Visits 30, 60, 90 days: Each period between consultations is 30 days, during which time the participant follows a free diet. At the end of each month, you will go for a medical consultation and be given the resveratrol-enriched wine. In the 4th consultation (90 days) the procedure of the first consultation will be repeated. That is, Consultation + Fasting blood extraction. Observations of eventual adverse events will be recorded; the information will be recorded in the CRF (Clinical Research Form). All the instruments used will be used only for you (disposable material), to avoid all types of contagion or infection. 3. Biochemical Analysis Determination of analysis to perform on the samples obtained from venous blood, initial and final at 90 days. samples. Venous blood will be obtained with heparin at both moments according to the protocol, with a 12-h fast. Start and end at 90 days. Determinations. Analysis of oxidative damage, analysis of enzymatic antioxidant defenses, inflammatory response in polymorphonuclear cells (PMN), red blood cells, plasma, and general biochemical analysis will be performed. Biochemical-Clinical Studies 1. Ferritin 2. Complete blood count w/Platelet count 3. Mean cell volume 4. RDW - Red Distribution Width 5. Ultrasensitive PCR 6. Glycemia 7. Creatinine 8. albumin 9. Alkaline Phosphatase 4. Body composition analysis The determination of the InBody analysis will be carried out at the beginning and at the end of the study. Statistical analysis: The statistical analysis was performed using the Student t-test for paired samples (Prism 7.0, GraphPad, San Diego, CA, USA). The Student t-test was selected to evaluate a single biomarker at a time in eight series of paired data (D0 vs. D90 for chronological and DNAm PhenoAge, muscle mass and fat mass) for each patient before and after the intervention. Results with p < 0.05 were considered significant.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 30, 2023
Est. primary completion date April 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 1.1 Minimum 40 years 1.2 Maximum 80 years 2. Gender 2.1 Male 2.2 Female 3. Habits 3.1 Regular wine consumers Exclusion criteria 1. Age 1.1 under 40 years 1.2 over 80 years 2. Modifications in treatments during the clinical trial 2.1 Pharmacological 2.2 Non-Pharmacological. 3. Pregnant women. 4. Women in planned pregnancy during the study period. 5. Women in the lactation period. 6. Patients who have been hospitalized for an infectious disease. 7. Patients suffering from autoimmune pathologies. 8. Patients who have cancer. 9. Patients with gastrointestinal pathologies. 10. Patients who have a history of liver disease. 11. Patients who have a history of kidney disease. 12. Patients who have hematological disease. 13. Patients who present disorders of the disease of psychiatric origin. 14. Patients who have epilepsy. 15. Patients with allergies to the active principles of: 15.1 Wine 15.2 Resveratrol.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Wine enriched with Resveratrol
Wine enriched with Resveratrol

Locations

Country Name City State
Argentina Raul Francisco Pastor Buenos Aires Buenos Aires City

Sponsors (2)

Lead Sponsor Collaborator
PINER Pastor Manfredi Winery University of Buenos Aires

Country where clinical trial is conducted

Argentina, 

References & Publications (4)

Fitzgerald KN, Hodges R, Hanes D, Stack E, Cheishvili D, Szyf M, Henkel J, Twedt MW, Giannopoulou D, Herdell J, Logan S, Bradley R. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging (Albany NY). 2021 Apr 12;13(7):9419-9432. doi: 10.18632/aging.202913. Epub 2021 Apr 12. Erratum In: Aging (Albany NY). 2022 Jul 27;14(14):5959. — View Citation

Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414. — View Citation

Pastor RF, Repetto MG, Lairion F, Lazarowski A, Merelli A, Manfredi Carabetti Z, Pastor I, Pastor E, Iermoli LV, Bavasso CA, Iermoli RH. Supplementation with Resveratrol, Piperine and Alpha-Tocopherol Decreases Chronic Inflammation in a Cluster of Older Adults with Metabolic Syndrome. Nutrients. 2020 Oct 15;12(10):3149. doi: 10.3390/nu12103149. — View Citation

Pastor RF, Restani P, Di Lorenzo C, Orgiu F, Teissedre PL, Stockley C, Ruf JC, Quini CI, Garcia Tejedor N, Gargantini R, Aruani C, Prieto S, Murgo M, Videla R, Penissi A, Iermoli RH. Resveratrol, human health and winemaking perspectives. Crit Rev Food Sci Nutr. 2019;59(8):1237-1255. doi: 10.1080/10408398.2017.1400517. Epub 2017 Dec 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Epigenetic age DNAm Phenoage 3 months
Primary InBody muscle mass Body composition 3 months
Primary Body composition InBody fat mass 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2